Serum Free Light Chain Analysis
Author: A. R. Bradwell
Publisher:
Published: 2006
Total Pages: 310
ISBN-13: 9780704425293
DOWNLOAD EBOOK →Author: A. R. Bradwell
Publisher:
Published: 2006
Total Pages: 310
ISBN-13: 9780704425293
DOWNLOAD EBOOK →Author: A. R. Bradwell
Publisher:
Published: 2008
Total Pages: 312
ISBN-13: 9780704427020
DOWNLOAD EBOOK →Author: Michael A. Linden
Publisher: Springer
Published: 2016-10-22
Total Pages: 0
ISBN-13: 9783319346588
DOWNLOAD EBOOK →This textbook will provide a comprehensive, state-of-the art review the field of diagnostic hematopathology as it’s applied to patients with plasma cell neoplasms. Particular emphasis will be placed on immunophenotypic data – immunohistochemistry and flow cytometry – as well as cytogenetics. We will also discuss how these ancillary data can predict prognosis and chemotherapeutic response. Plasma Cell Neoplasms will serve as a very useful resource for physicians and researchers interested in the plasma cell myeloma diagnosis, therapy, and research. It will provide a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters will be written by experts in their fields and will include the most up to date scientific and clinical information.
Author: Morie A. Gertz
Publisher: Springer Science & Business Media
Published: 2013-10-01
Total Pages: 311
ISBN-13: 1461485207
DOWNLOAD EBOOK →This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
Author: Kathleen Deska Pagana
Publisher: Mosby
Published: 2017-10-27
Total Pages: 1137
ISBN-13: 9780323446631
DOWNLOAD EBOOK →"Succeed iin clinicals and practice with this user-friendly diagnostic and lab test manual. Writing care plans, understanding and performing tests, and interpreting test results is made easier with Mosby's Manual of Diagnostic and Laboratory Tests, 6th Edition. This essential resource provides clear, concise coverage of over 700 of the most commonly performed diagnostic and laboratory tests. Valuable in academic and clinical settings alike, it is beloved for its full-color design, user-friendly organization, andillustrations that help clarify key concepts" -- Back cover.
Author: William Clarke
Publisher: Academic Press
Published: 2020-06-11
Total Pages: 1070
ISBN-13: 0128158336
DOWNLOAD EBOOK →Contemporary Practice in Clinical Chemistry, Fourth Edition, provides a clear and concise overview of important topics in the field. This new edition is useful for students, residents and fellows in clinical chemistry and pathology, presenting an introduction and overview of the field to assist readers as they in review and prepare for board certification examinations. For new medical technologists, the book provides context for understanding the clinical utility of tests that they perform or use in other areas in the clinical laboratory. For experienced laboratorians, this revision continues to provide an opportunity for exposure to more recent trends and developments in clinical chemistry. Includes enhanced illustration and new and revised color figures Provides improved self-assessment questions and end-of-chapter assessment questions
Author: Manorama Bhargava
Publisher: Springer Nature
Published: 2021-02-13
Total Pages: 246
ISBN-13: 9813347996
DOWNLOAD EBOOK →This book is a compendium of case studies in hematologic malignancies such as acute leukemias, myelodysplastic and myeloproliferative neoplasms, chronic leukemias and multiple myeloma covering cytogenetics (karyotyping Fluorescence in sitn hybridization (FISH)) and molecular studies in detail. The first few chapters describe the methodology employed for karyotyping, FISH and Real Time PCR technology conducive to establishment of these labs if required. Each case study is described in detail by including the clinical history of the patient, findings of peripheral blood, bone marrow aspirate and bone biopsy morphological details. This is then followed by flowcytometric immunophenotyping, cytogenetic and molecular observations leading collectively to a final diagnosis, A discussion follows based on the relevance of this data in informing the prognosis, treatment response and survival in these patients. Additionally, this data serves as a key determinant for clinical decision making involving evidence based rational management of patients including targeted therapy. For better understanding, each case study is accompanied by black and white or colour images as appropriate. This book is a source of learning and a valuable read for clinical hematologists, hematopathologists, medical oncologists, residents, interns, DM Hematology students and DNB Hematology students as well.
Author: Madhumathi Rao
Publisher:
Published: 2012
Total Pages:
ISBN-13:
DOWNLOAD EBOOK →Plasma cell dyscrasias (PCDs) are a group of clonal disorders characterized by the uninhibited expansion of a monoclonal population of malignant plasma cells. Plasma cells arise from B cells in the bone marrow and produce immunoglobulins that constitute the body's normal humoral immune response. The immunoglobulin molecule is composed of a heavy chain and a light chain. Plasma cells normally produce light chains in excess that do not bind to heavy chains to form a complete immunoglobulin molecule and instead enter the bloodstream as free light chains (FLCs). In PCDs, each abnormally expanded clone of malignant plasma cells produce an excess of either intact immunoglobulin or FLCs of a single type called a monoclonal protein (M-protein) or paraprotein. The serum FLC (SFLC assay (the Freelite" Assay), The Binding Site Ltd., Birmingham, United Kingdom) was introduced in 2001 to measure the FLC component in particular. The SFLC assay works by recognizing an epitope that is detectable only on light chains that are not bound to the heavy chain of the immunoglobulin molecule (i.e., FLCs) in the serum. This is the sole SFLC assay approved by the U.S. Food and Drug Administration. It detects low concentrations of FLCs and can measure the ratio of kappa chains to lambda chains. It has been suggested that the SFLC assay could play an adjunctive role in screening, diagnosis, monitoring, and prognosis of PCDs in high-risk populations. The International Myeloma Working Group (IMWG) currently considers the SFLC assay to be an adjunct to traditional tests. The assay could allow for quantitative monitoring of response and remission after treatment and provide prognostic information, potentially reducing the need for frequent bone marrow biopsy for purposes of quantifying plasma cells, which is required as part of stringent monitoring for monoclonal gammopathy of undetermined significance (MGUS) progression to multiple myeloma (MM) or defining disease remission, and potentially could be used in conjunction with serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE) to replace urine tests that require 24-hour collection (urine protein electrophoresis [UPEP] and urine immunofixation electrophoresis [UIFE]), which could simplify diagnosis and disease monitoring. The SFLC assay may also be the only means of detecting a disease marker in some disease settings: nonsecretory MM, where SFLCs are often the only marker of the disease; AL amyloidosis (systemic amyloidosis in which amyloid [A] proteins derived from immunoglobulin light chains [L] are deposited in tissue), where low monoclonal protein (M-protein) concentrations may not be detected by means of conventional techniques; and light chain MM, where the M-protein consists only of FLCs. These diagnostic applications have yet to be validated and standardized. Thus, although the SFLC assay has been in use for a decade, it remains unclear how best to incorporate it into clinical practice.
Author: Eric P. Cohen
Publisher: Oxford University Press, USA
Published: 2010-11-11
Total Pages: 382
ISBN-13: 0199580197
DOWNLOAD EBOOK →Cancer and the Kidney covers the challenging overlap area of nephrology and oncology, both in terms of kidney problems in cancer patients, and cancer that affects kidney patients, including assessment of kidney function, to paraneoplastic disorders, acquired cysts and native kidney cancers, and all points inbetween.
Author: U. S. Department of Health and Human Services
Publisher: Createspace Independent Pub
Published: 2013-05-23
Total Pages: 54
ISBN-13: 9781489553522
DOWNLOAD EBOOK →Plasma cell dyscrasias (PCDs) are a group of clonal disorders characterized by the uninhibited expansion of a monoclonal population of malignant plasma cells. Plasma cells arise from B cells in the bone marrow and produce immunoglobulins that constitute the body's normal humoral immune response. The immunoglobulin molecule is composed of a heavy chain and a light chain. Plasma cells normally produce light chains in excess that do not bind to heavy chains to form a complete immunoglobulin molecule and instead enter the bloodstream as free light chains (FLCs). In PCDs, each abnormally expanded clone of malignant plasma cells produce an excess of either intact immunoglobulin or FLCs of a single type called a monoclonal protein (Mprotein) or paraprotein. The serum FLC (SFLC assay (the Freelite(tm) Assay, The Binding Site Ltd., Birmingham, United Kingdom) was introduced in 2001 to measure the FLC component in particular. The SFLC assay works by recognizing an epitope that is detectable only on light chains that are not bound to the heavy chain of the immunoglobulin molecule (i.e., FLCs) in the serum. It has been suggested that the SFLC assay could play an adjunctive role in screening, diagnosis, monitoring, and prognosis of PCDs in high-risk populations. The assay could allow for quantitative monitoring of response and remission after treatment and provide prognostic information, potentially reducing the need for frequent bone marrow biopsy for purposes of quantifying plasma cells, which is required as part of stringent monitoring for monoclonal gammopathy of undetermined significance (MGUS) progression to multiple myeloma (MM) or defining disease remission, and potentially could be used in conjunction with serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE) to replace urine tests that require 24-hour collection (urine protein electrophoresis [UPEP] and urine immunofixation electrophoresis [UIFE]), which could simplify diagnosis and disease monitoring. The SFLC assay may also be the only means of detecting a disease marker in some disease settings: nonsecretory MM, where SFLCs are often the only marker of the disease; AL amyloidosis (systemic amyloidosis in which amyloid [A] proteins derived from immunoglobulin light chains [L] are deposited in tissue), where low monoclonal protein (M-protein) concentrations may not be detected by means of conventional techniques; and light chain MM, where the M-protein consists only of FLCs. The following Key Questions are reviewed. KQ 1: Does adding the SFLC assay and the kappa/lambda ratio to traditional testing (SPEP, UPEP, SIFE, or UIFE), compared with traditional testing alone, improve the diagnostic accuracy for PCDs (MGUS, MM, nonsecretory MM, or AL amyloidosis) in undiagnosed patients suspected of having a PCD? KQ 2: As compared with traditional tests, how well does the SFLC assay independently predict progression to MM in patients with MGUS? KQ 3: In patients with an existing diagnosis of PCD (MM, nonsecretory MM, or AL amyloidosis), does the use of the SFLC assay result in different treatment decisions as compared with traditional tests? Does the use of the SFLC assay affect the management of patients by allowing for earlier institution of specific therapies? Does the use of the SFLC assay influence the duration of treatment? Does the use of the SFLC assay influence the type of treatment (e.g., radiation therapy)? KQ4: In patients with an existing diagnosis of PCD (MM, nonsecretory MM, or AL amyloidosis), is the SFLC assay better than traditional tests in indicating how the patient responds to treatment and of outcomes (overall survival, disease-free survival, remission, light chain escape, and quality of life)? KQ 5: In patients with an existing diagnosis of PCD (MM, nonsecretory MM, or AL amyloidosis), does the use of the SFLC assay reduce the need for other interventions (e.g., bone marrow biopsy)?